Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RGBP-Believes They Have Cracked The NR2F6 Activation Code To Unleash The Cancer-Killing Potential Of A Patient's Own Immune System

|About: Regen Biopharma, Inc. (RGBP)
Summary

NR2F6 - Cancer Killing Potetial

Killing Cancer Using a Patients Immune System

Key Drugs/Treatment in Pipeline

Multiple Cancers, Rare Blood & Auto Immune Diseases, Lupus

www.regenbiopharmainc.com

Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

PR NewswireSeptember 6, 2017

Comment

Researchers Believe They Have Cracked the NR2F6 Activation Code

SAN DIEGO, September 6, 2017 /PRNewswire/ --

Regen BioPharma Inc. (RGBP) and (RGBPP), in conjunction with its medicinal chemistry partner, ChemDiv, Inc., believes it has made a fundamental discovery in developing small molecule drugs that activate NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 have key structural elements that make them active and specific.  

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

Regen BioPharma, Inc. Researchers Identify Key Structure in Compounds that Activate NR2F6

We have said for sometime we believe $RGBP is a potential buyout target. A Long Play. Now just imagine and/or think, are you in position if or when this day comes?

Regen has had major breakthroughs and great results with their new drug HemaXellerate during "Human" clinical trials for the treatment of aPlastic Anemia, a rare blood disease. They have also during this process discovered a new, much larger market for HemaXellerate. $RGBP has discovered that HemaXellerate is effective in treating Bone Marrow Suppression, a very painful condition as a result of chemo therapy.

Bristol Myers Squibb (BMS) just announced today a $2.3 Billion acquisition of IMF Therapeutics. With what Regen is accomplishing with NR2F6, one has to think, one day, someone, a much larger Pharma company will come knocking on $RGBP's door.

David Koos (CEO) of Regen - Addresses Potential Impact of Recent Bristol Myers Squibb (BMS) $2.3 Billion Acquisition of IMF Therapeutics and similarities.

https://finance.yahoo.com/news/regen-biopharma-inc-addresses-potential-110000864.html

For more information on (OTCQB:OTCQB:RGBP) Read:

#RGBP 10Q- Quarterly Financials http://bit.ly/2vfMO10  ...

Recent Updates/News & New Web Site http://bit.ly/2wpYiNM  ...

If you have any questions or need more information-Contact

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com(OTCBB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.comor by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.